[Alzheimer Disease].
Year: 2007
Type: article
Abstract: OBJECTIVE: Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine. QUALITY OF EVIDENCE: The conclusions and recommendations in this article are based on data from studies providing level I and level II evidence. MAIN MESSAGE: Recent data suggest that vascular disease plays an important role in the physiopathology of AD. Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD. CONCLUSION: The prevention and treatment of vascular risk factors should be an integral part of the management of AD. For the treatment of moderate to severe AD, memantine is a new option that is effective and well tolerated.
Source: Europe PMC (PubMed Central)
Author: Fadi Massoud
Institution: Hôpital Notre-Dame
Language: French
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2227383580